Lotte Biologics is expanding its collaboration with Ottimo Pharma, a biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies, strengthening a growing strategic partnership.
This expanded collaboration extends beyond manufacturing, bringing together Ottimo Pharma and Lotte Biologics to advance Ottimo Pharma’s biparatopic antibody, OTP-01, toward launch readiness. Lotte’s development team, located at the Syracuse Bio Campus in New York, will support commercial process development and characterisation activities.
As a pure-play CDMO, Lotte Biologics provides integrated services across development and manufacturing, supported by its dual-site strategy spanning the Syracuse Bio Campus in the US and the Songdo Bio Campus in Korea. This global platform enables consistent quality, operational flexibility, and supply reliability.
James Park, CEO of Lotte Biologics, said, “The continued trust from our partners reinforces our belief that a CDMO should not only deliver, but truly understand and advance our clients’ molecules. At Lotte Biologics, we are committed to supporting the full lifecycle of our clients’ pipelines, ensuring speed, quality, and scalability as they progress toward commercialisation and patient impact.”
Spencer Fisk, chief technical and quality officer, said, “Ottimo Pharma values its strong collaboration with Lotte Biologics, whose team has demonstrated exceptional partnership, quality, and speed of execution. Their ability to move quickly and reliably was instrumental in helping us initiate our Phase 1/2a study with industry-leading speed, and we are pleased to expand this relationship as we continue development of OTP-01.”
